Baxter looks to keep its grip on hemophilia market with new FDA filing

Hemophilia leader Baxter ($BAX) isn't quite ready to cede its market share to long-acting newcomers from Biogen Idec ($BIIB). It's filed an FDA application for a long-lasting drug of its own in a hemophilia A space that will be key for the drugmaker once it spins off its biopharma unit--set to become new company Baxalta--next year. Report | More